New Daily Pill Orforglipron Shows Promise in Maintaining Weight Loss Post-Obesity Jabs
A recent trial has revealed that a daily pill, orforglipron, could help individuals maintain weight loss after discontinuing injectable obesity treatments. The study, presented at the European Congress on Obesity 2026 and published in Nature Medicine, involved 376 U.S. participants who had been using GLP-1 injections like tirzepatide and semaglutide. After switching to orforglipron, participants retained a significant portion of their weight loss compared to those on a placebo. The trial, funded by Eli Lilly, suggests that orforglipron could prevent the need for long-term medications associated with obesity-related diseases. 
